The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man
References (21)
- et al.
Polymorphic hydroxylation of debrisoquine in man
Lancet
(1977) - et al.
In vitro studies of induction and inhibition of drug oxidation in man
Pharmacol Ther
(1987) - et al.
Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
Life Sci
(1984) - et al.
Bufuralol 1'-hydroxylase activity of the rat: Strain differences and the effects of inhibitors
Biochem Pharmacol
(1986) - et al.
Protein measurement with the Folin phenol reagent
J Biol Chem
(1951) - et al.
The debrisoquine gene: A gene of multiple consequence
- et al.
Low frequency of slow debrisoquine hydroxylation in a Natlve Chinese population
Lancet
(1987) - et al.
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
Clin Pharmac Ther
(1985) - et al.
Debrisoquine 4-hydroxylase: characterization of a new P-450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism
DNA
(1987) - et al.
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
Nature (Lond)
(1988)
Cited by (144)
Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects
2021, Neurochemistry InternationalCitation Excerpt :It suggests that asenapine has a higher affinity for the active centre of human CYP2D6 than rat CYP2D enzyme. This kind of differences in the Ki values between human and rat liver CYP2D enzymes were also observed for the specific CYP2D6 inhibitor quinidine, typical and atypical neuroleptics and antidepressant drugs (Daniel, 2005; Daniel et al., 2002; Kobayashi et al., 1989; Steiner et al., 1988). Interestingly, the inhibition of rat CYP2D enzyme in the liver is about 10 times greater than in the brain (Ki = 385 μM).
Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study
2015, Pharmacological ReportsThe truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A
2015, European Journal of Pharmaceutical SciencesHow pre-marketing data can be used for predicting the weight of drug interactions in clinical practice
2013, European Journal of Internal MedicineComparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys
2010, Chemico-Biological Interactions
- ∗
Present address: Department of Pharmacology, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan.
- †
Present address: Clinical Mass. Spec. Lab., Department of Paediatrics, Children's Hospital Medical Center, Elland & Bethesda Avenues, Cincinnati, OH 45229, U.S.A.